This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $291.23, marking a -0.06% move from the previous day.
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $295.11 in the latest trading session, marking a +0.44% move from the prior day.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.18%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.40, moving -0.18% from the previous trading session.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $291.10, marking a +1.68% move from the previous day.
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.
Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.
Can Vertex (VRTX) Stock Continue to Grow Earnings?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).
Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing
by Zacks Equity Research
Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.
Market to Stay Northbound Despite Volatility: 5 Growth Picks
by Nalak Das
The worst of the market is long over. Although, short-term volatility will continue due to COVID-19, overall market movement will remain positively sloped.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.56%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $291.18, moving -1.56% from the previous trading session.
The Zacks Analyst Blog Highlights: Tesla, NVIDIA, ServiceNow, Vertex and Activision Blizzard
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, NVIDIA, ServiceNow, Vertex and Activision Blizzard
Gilead to Buy 49.9% Stake in Private Biotech for $275M
by Zacks Equity Research
Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What Pandemic? These 5 Large Caps Are Up More Than 25% YTD
by Nalak Das
Several large-caps have skyrocketed during the first half of 2020 while the broad market is yet to fully recover from the impacts of pandemic.
Biogen Falls on Patent Loss of MS Drug Tecfidera to Mylan
by Zacks Equity Research
The U.S. District Court of West Virginia gives a ruling against Biogen (BIIB) over a patent dispute with generic drugmaker Mylan pertaining to its best-selling multiple sclerosis drug, Tecfidera.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $279.19, marking a -0.32% move from the previous day.
The Zacks Analyst Blog Highlights: Boxlight, ChannelAdvisor, Vertex Pharmaceuticals, Murphy USA and Sprouts Farmers Market
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boxlight, ChannelAdvisor, Vertex Pharmaceuticals, Murphy USA and Sprouts Farmers Market
Zacks.com featured highlights include: Vertex Pharmaceuticals, Sprouts Farmers Market, Dollar General and Tractor Supply Company
by Zacks Equity Research
Zacks.com featured highlights include: Vertex Pharmaceuticals, Sprouts Farmers Market, Dollar General and Tractor Supply Company
Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Here Are 4 Stocks With Remarkable Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardships.
3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic
by Ekta Bagri
We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.
Fed's Bond-Buying Plan Eases Second-Wave Fears: 5 Picks
by Tirthankar Chakraborty
With the Fed announcing that it will buy corporate bonds to help an economy battered by the coronavirus pandemic, the stock market has found a new lease of life.
6 Safe Stocks to Weather the Storm
by Sejuti Banerjea
These companies have strong balance sheets and are expected to grow over the next few years.